Sohmiya M, Kato Y
Department of Medicine, Shimane Medical University, Izumo, Japan.
J Endocrinol Invest. 2000 Jan;23(1):31-6. doi: 10.1007/BF03343673.
We studied the effect of treatment with recombinant human GH in an anemic patient with panhypopituitarism in which hemoglobin (Hb) concentration remained as low as 11.0 g/dl in spite of appropriate replacement with thyroid and adrenocortical hormones. Recombinant human GH was subcutaneously and constantly infused for 12 months using a portable syringe pump at a rate of 0.25 U/kg/week. After the treatment with human GH plasma erythropoietin (EPO) levels increased from 12.2 to 25.1 mIU/ml, with a concomitant increase of Hb concentration to 13.6 g/dl. When the administration of human GH was interrupted, both plasma EPO levels and Hb concentrations decreased. There was a close correlation between plasma GH and EPO levels before and during the human GH administration (y=2.444x+1 3.423, r=0.641, p<0.05). Plasma GH levels were well correlated with Hb concentrations before and during human GH administration (y=0.529x+11.313, r=0.690, p<0.01). Plasma IGF4 levels were also correlated with Hb concentrations (y=0.007x+10.874, r=0.832, p<0.001), but not with plasma EPO levels. These findings suggest that GH treatment may be useful in anemic patients with panhypopituitarism.
我们研究了重组人生长激素（GH）治疗对一名全垂体功能减退贫血患者的影响。尽管给予了适当的甲状腺和肾上腺皮质激素替代治疗，但该患者的血红蛋白（Hb）浓度仍低至11.0 g/dl。使用便携式注射泵以0.25 U/kg/周的速率皮下持续输注重组人生长激素12个月。使用重组人生长激素治疗后，血浆促红细胞生成素（EPO）水平从12.2 mIU/ml增至25.1 mIU/ml，同时Hb浓度增至13.6 g/dl。当中断重组人生长激素给药后，血浆EPO水平和Hb浓度均下降。在给予重组人生长激素之前及期间，血浆GH水平与EPO水平密切相关（y = 2.444x + 13.423，r = 0.641，p < 0.05）。在给予重组人生长激素之前及期间，血浆GH水平与Hb浓度密切相关（y = 0.529x + 11.313，r = 0.690，p < 0.01）。血浆胰岛素样生长因子4（IGF4）水平也与Hb浓度相关（y = 0.007x + 10.874，r = 0.832，p < 0.001），但与血浆EPO水平无关。这些发现表明，生长激素治疗可能对全垂体功能减退的贫血患者有用。
